Endocrine-Related Cancer

Article	Citations
PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)	74
COVID-19 and androgen-targeted therapy for prostate cancer patients	59
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms	58
Redifferentiation of radioiodine-refractory thyroid cancers	50
Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms	47
Thyroid dysfunction and cancer incidence: a systematic review and meta-analysis	47
Androgen hazards with COVID-19	45
Innovative imaging of insulinoma: the end of sampling? A review	42
Neuroendocrine neoplasm update: toward universal nomenclature	42
The tumor microenvironment and immune responses in prostate cancer patients	34
Molecular profiling for acromegaly treatment: a validation study	33
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading	33
Squamous cell carcinoma of thyroid: a unique type of cancer in World Health Organization Classification	32
Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature	32
Therapy considerations in neuroendocrine prostate cancer: what next?	32
Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?	30
The role of vitamin D in breast cancer risk and progression	30
HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas	29
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop	29
Thyroid cancer in the age of COVID-19	29
Redifferentiation-facilitated radioiodine therapy in thyroid cancer	28
Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns	28
Obese adipose tissue extracellular vesicles raise breast cancer cell malignancy	27
The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)	26
The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer	25

The complex regulation of NIS expression and activity in thyroid and extrathyroidal tissues	24
Molecular alterations in Hürthle cell nodules and preoperative cancer risk	23
Genetic profile of advanced thyroid cancers in relation to distant metastasis	22
Heterogeneity of genomic profile in patients with HER2-positive breast cancer	22
New therapeutic opportunities for women with low-grade serous ovarian cancer	22
Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer	22
FOXO1 as a tumor suppressor inactivated via AR/ERβ signals in urothelial cells	22
The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches	22
GABPA-dependent down-regulation of DICER1 in follicular thyroid tumours	22
Extrapulmonary poorly differentiated NECs, including molecular and immune aspects	21
50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?	21
The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment	20
The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience	20
Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas	20
Genotype of CDC73 germline mutation determines risk of parathyroid cancer	20
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: New and future perspectives for parathyroid carcinoma	20
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review	19
Antiangiogenic therapies for pheochromocytoma and paraganglioma	19
Management changes for patients with endocrine-related cancers in the COVID-19 pandemic	19
Fibroblast growth factors signaling in bone metastasis	17
p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer	17
Genomic classification of benign adrenocortical lesions	17
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer	17
Androgen receptor mutations for precision medicine in prostate cancer	17
SREBP1 promotes invasive phenotypes by upregulating CYR61/CTGF via the Hippo-YAP pathway	17
Phosphodiesterase 2A and 3B variants are associated with primary aldosteronism	17
Risk factors for intraoperative complications in pheochromocytomas	17
Role of circadian rhythm disorders on EMT and tumour–immune interactions in endocrine-related cancers	17
Novel insights in cell cycle dysregulation during prostate cancer progression	16
Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer	16
Targeting EML4-ALK gene fusion variant 3 in thyroid cancer	16
Neuroendocrine neoplasms of lung, pancreas and gut: a morphology-based comparison	15
Tailoring the approach to radioactive iodine treatment in thyroid cancer	15
B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors	15
Advanced RAI-refractory thyroid cancer: an update on treatment perspectives	15
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC	14
KLF5 and NFYA factors as novel regulators of prostate cancer cell metabolism	14
A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/− rats	14
Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC	14
Cullin 3 targets the tumor suppressor gene ARMC5 for ubiquitination and degradation	14
Chloroquine induces apoptosis in pancreatic neuroendocrine neoplasms via endoplasmic reticulum stress	14
Genome-wide crosstalk between steroid receptors in breast and prostate cancers	14
Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets	14
Gene expression profile in metastatic and non-metastatic parathyroid carcinoma	14
Critical appraisal of MGMT in digestive NET treated with alkylating agents	14
Metabolic and hormonal remodeling of colorectal cancer cell signaling by diabetes	14
Follow-up of patients with thyroid cancer and antithyroglobulin antibodies: a review for clinicians	13
Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging	13
Molecular connections between circadian rhythm and genome maintenance pathways	13
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET	13

Fishing for neuroendocrine tumors	13
The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitors	13
Mass spectrometry-based steroid profiling in primary bilateral macronodular adrenocortical hyperplasia	13
Exercise intensity and markers of inflammation during and after (neo-) adjuvant cancer treatment	12
Targeted genomic analysis of 364 adrenocortical carcinomas	12
The thyroid risk score (TRS) for nodules with indeterminate cytology	12
Adiponectin receptor activation inhibits prostate cancer xenograft growth	12
Metastatic medullary thyroid carcinoma: a new way forward	12
The prognostic value of androgen receptor (AR) in HER2-enriched metastatic breast cancer	12
The role of extracellular vesicles in prostate cancer with clinical applications	12
FOXE1 regulates migration and invasion in thyroid cancer cells and targets ZEB1	12
Changing biological behaviour of NETs during the evolution of the disease: progress on progression	12
CRISP3 expression drives prostate cancer invasion and progression	12
Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview	12
TNM 8th edition in thyroid cancer staging: is there an improvement in predicting recurrence?	12
IGF2 drives formation of ileal neuroendocrine tumors in patients and mice	11
Improved pasireotide response in USP8 mutant corticotroph tumours in vitro	11
USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs	11
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine	11
Translating the immune microenvironment of thyroid cancer into clinical practice	11
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: GPR101, an orphan GPCR with roles in growth and pituitary tumorigenesis	11
Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma	11
Neutrophil elastase from myeloid cells promotes TSC2-null tumor growth	11
Regulation of docetaxel chemosensitivity by NR2F6 in breast cancer	11
Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures	11
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The roles of AIP and GPR101 in familial isolated pituitary adenomas (FIPA)	10
The role of membrane mucin MUC4 in breast cancer metastasis	10
Treatment outcomes of advanced digestive well-differentiated grade 3 NETs	10
Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers	10
Leptin-elicited PBX3 confers letrozole resistance in breast cancer	10
Serine synthesis influences tamoxifen response in ER+ human breast carcinoma	9
Steroid receptor coactivator-3 as a target for anaplastic thyroid cancer	9
A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy	9
Na+/I− symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy	9
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives	9
Inhibition of GATA2 in prostate cancer by a clinically available small molecule	9
The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings	9
Dsg2-mediated c-Met activation in anaplastic thyroid cancer motility and invasion	9
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma	8
Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma	8
Advances in paraganglioma–pheochromocytoma cell lines and xenografts	8
Thyroid status regulates the tumor microenvironment delineating breast cancer fate	8
SYT7 plays a role in promoting thyroid cancer by mediating HMGB3 ubiquitination	8
Stress hormone norepinephrine incites resistance of oral cancer cells to chemotherapy	8
Exploring stem cell biology in pituitary tumors and derived organoids	8
Somatostatin receptor radionuclide therapy in neuroendocrine tumors	8
TREM1 fosters an immunosuppressive tumor microenvironment in papillary thyroid cancer	8
Pre-diagnosis thyroid hormone dysfunction is associated with cancer mortality	8
Outcome of patients with intrathyroidal thymic carcinoma: a pooled analysis	8
Targeting androgen receptor signaling: a historical perspective	8
Adrenal tumors provide insight into the role of cortisol in NK cell activity	8
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis	8
Alert to US physicians: DHEA, widely used as an OTC androgen supplement, may exacerbate COVID-19	8
Immunotherapy-induced isolated ACTH deficiency in cancer therapy	8
Maternal obesity increases offspring’s mammary cancer recurrence and impairs tumor immune response	8
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)	8
Loss of sdhb in zebrafish larvae recapitulates human paraganglioma characteristics	7
ARMC5 variants in PRKAR1A-mutated patients modify cortisol levels and Cushing’s syndrome	7
Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline	7
Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms	7
Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer	7
Remodelling of colorectal cancer cell signaling by microbiota and immunity in diabetes	7
Evaluation of modifiable factors and polygenic risk score in thyroid cancer	7
Prognostic transcriptome classes of duodenopancreatic neuroendocrine tumors	7
New drug delivery strategies targeting the GnRH receptor in breast and other cancers	7
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review	7
Health-related quality of life in neuroendocrine neoplasia: a critical review	7
Integrin αvβ3-dependent thyroid hormone effects on tumour proliferation and vascularisation	7
Dysregulation of splicing variants and spliceosome components in breast cancer	7
Effect of TSH levels during active surveillance of PTMC according to age	7
Epidural anesthesia and hypotension in pheochromocytoma and paraganglioma	7
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial	7
AR-dependent phosphorylation and phospho-proteome targets in prostate cancer	7
Mammary carcinoma in aged gerbil mothers after endocrine disruption in pregnancy and lactation	6
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal	6
FAM172A promotes follicular thyroid carcinogenesis and may be a marker of FTC	6
Microglial NLRP3 inflammasome activation-mediated inflammation promotes prolactinoma development	6
Can TP53-mutant follicular adenoma be a precursor of anaplastic thyroid carcinoma?	6
Functional significance of germline EPAS1 variants	6
Percutaneous ablation of low-risk papillary thyroid cancer	6

Hypothyroidism induces oxidative stress and DNA damage in breast	6
Global longitudinal strain as a marker for systolic function in patients with pheochromocytomas	6
Congenital hypothyroidism and thyroid cancer	6
Cancer-associated adipocytes release FUCA2 to promote aggressiveness in TNBC	6
PRKACB variants in skeletal disease or adrenocortical hyperplasia: effects on protein kinase A	6
Development of improved SRC-3 inhibitors as breast cancer therapeutic agents	6
Aldosterone-producing nodules and CYP11B1 signaling correlate in primary aldosteronism	6
Cancer clocks in tumourigenesis: the p53 pathway and beyond	6
Incident atrial fibrillation in patients with differentiated thyroid cancer: a meta-analysis	6
Disease-free survival as a measure of overall survival in resected pancreatic endocrine neoplasms	6
The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas	6
Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations	6
Leptin antagonism inhibits prostate cancer xenograft growth and progression	6
Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma	6
100 years of the Warburg effect: a historical perspective	6
Radioiodine treatment: an historical and future perspective	5
AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer	5
ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways	5
Amphiregulin retains ERα expression in acquired aromatase inhibitor resistant breast cancer cells	5
Real-time, high-resolution imaging of tumor cells in genetically engineered and orthotopic models of thyroid cancer	5
Update on the genetics of paragangliomas	5
Aggressive versus indolent insulinomas: new clinicopathological insights	5
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study	5
Urinary androgens excretion patterns and prostate cancer in Mexican men	5
Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs)	5
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needs	5
Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus	5
BRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation	5
Diagnostic and management strategies for pNETs in Von Hippel–Lindau: a systematic review	5
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2	5
Predicting symptomatic mesenteric mass in small intestinal neuroendocrine tumors using radiomics	4
Serum TSH is not a risk factor for malignancy of pediatric thyroid nodules	4
Target therapies plus somatostatin analogs in NETs: a network meta-analysis	4
Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites	4
Frequent copy number gains of SLC2A3 and ETV1 in testicular embryonal carcinomas	4
Key factors for effective mitotane therapy in children with adrenocortical carcinoma	4
Prognostic value of the Weiss and Wieneke (AFIP) scoring systems in pediatric ACC – a mini review	4
Efficacy of adavosertib therapy against anaplastic thyroid cancer	4
An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms	4
Single nucleotide polymorphisms in matrix metalloproteinase 2 (MMP2) enhance BRAFV600E mutation-mediated oncogenicity and invasiveness of papillary thyroid cancer cells	4
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms	4
Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers	4
Preclinical evaluation of targeted therapies in Sdhb-mutated tumors	4
Malignant thyroid teratoma: an integrated analysis of case series/case reports	4
Thyroid autoimmunity, thyroglobulin autoantibodies, and thyroid cancer prognosis	4
Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors	4
The association between serum concentration of thyroid hormones and thyroid cancer: a cohort study	4
Mendelian randomization supports a causative effect of TSH on thyroid carcinoma	4
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Early thyroidectomy in multiple endocrine neoplasia: a four decade experience	4
A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy	4